MedTrace Logo

Magnesium Treating Subarachnoid Hemorrhage Vasospasm

NCT04613960 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-09-13

No results posted yet for this study

Summary

A randomized clinical trial investigating magnesium sulphate ability to reduce risk of cerebral vasospasm after acute subarachnoid hemorrhage hence improving outcome particularly in haptoglobin 2-2 patients who are highly susceptible for severe complications after subarachnoid hemorrhage.

Conditions

  • Subarachnoid Hemorrhage, Aneurysmal
  • Cerebral Vasospasm

Interventions

DRUG

Magnesium sulfate

MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset

DRUG

normal saline

Placebo treatment

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • Health Insurance Organization, Egypt

    collaborator UNKNOWN

  • General Committee of Teaching Hospitals and Institutes, Egypt

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2023-12-31
Completion
2024-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04613960 on ClinicalTrials.gov